# Apyx Medical Corp: financial statements, quarterly

APYX · Nasdaq · CIK 719135 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/apyx.md) · [Financials](/companies/apyx/financials.md) · [Filings](/companies/apyx/filings.md) · [Insiders](/companies/apyx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/apyx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [12.0](/filings/0001437749-24-034193.md) | [14.7 d](/filings/0001437749-25-007521.md) | [10.2](/filings/0001437749-25-015356.md) | [12.1](/filings/0001437749-25-025422.md) | [11.5](/filings/0001437749-25-033499.md) | [14.2 d](/filings/0001437749-26-007471.md) | [9.4](/filings/0001437749-26-015652.md) | [11.4](/filings/0001437749-26-026346.md) | [12.9](/filings/0001437749-25-033499.md) | [19.2 d](/filings/0001437749-26-007471.md) | [12.5](/filings/0001437749-26-015652.md) | [13.9](/filings/0001437749-26-026346.md) |
| Cost of revenue | $m | [4.0](/filings/0001437749-24-034193.md) | [5.7 d](/filings/0001437749-25-007521.md) | [4.3](/filings/0001437749-25-015356.md) | [4.7](/filings/0001437749-25-025422.md) | [4.5](/filings/0001437749-25-033499.md) | [5.3 d](/filings/0001437749-26-007471.md) | [3.8](/filings/0001437749-26-015652.md) | [4.3](/filings/0001437749-26-026346.md) | [4.6](/filings/0001437749-25-033499.md) | [7.2 d](/filings/0001437749-26-007471.md) | [4.6](/filings/0001437749-26-015652.md) | [5.0](/filings/0001437749-26-026346.md) |
| Gross profit | $m | [8.0](/filings/0001437749-24-034193.md) | [8.9 d](/filings/0001437749-25-007521.md) | [5.9](/filings/0001437749-25-015356.md) | [7.5](/filings/0001437749-25-025422.md) | [7.0](/filings/0001437749-25-033499.md) | [9.0 d](/filings/0001437749-26-007471.md) | [5.7](/filings/0001437749-26-015652.md) | [7.1](/filings/0001437749-26-026346.md) | [8.3](/filings/0001437749-25-033499.md) | [12.0 d](/filings/0001437749-26-007471.md) | [7.9](/filings/0001437749-26-015652.md) | [8.9](/filings/0001437749-26-026346.md) |
| Research and development | $m | [1.4](/filings/0001437749-24-034193.md) | [1.4 d](/filings/0001437749-25-007521.md) | [1.4](/filings/0001437749-25-015356.md) | [1.4](/filings/0001437749-25-025422.md) | [1.1](/filings/0001437749-25-033499.md) | [1.1 d](/filings/0001437749-26-007471.md) | [0.8](/filings/0001437749-26-015652.md) | [0.8](/filings/0001437749-26-026346.md) | [0.8](/filings/0001437749-25-033499.md) | [0.9 d](/filings/0001437749-26-007471.md) | [0.8](/filings/0001437749-26-015652.md) | [0.8](/filings/0001437749-26-026346.md) |
| Selling, general and administrative | $m | [4.8](/filings/0001437749-24-034193.md) | [6.7 d](/filings/0001437749-25-007521.md) | [4.9](/filings/0001437749-25-015356.md) | [4.8](/filings/0001437749-25-025422.md) | [4.3](/filings/0001437749-25-033499.md) | [4.8 d](/filings/0001437749-26-007471.md) | [3.5](/filings/0001437749-26-015652.md) | [4.3](/filings/0001437749-26-026346.md) | [3.7](/filings/0001437749-25-033499.md) | [4.6 d](/filings/0001437749-26-007471.md) | [3.6](/filings/0001437749-26-015652.md) | [5.3](/filings/0001437749-26-026346.md) |
| Operating income | $m | [(4.6)](/filings/0001437749-24-034193.md) | [(5.8) d](/filings/0001437749-25-007521.md) | [(6.6)](/filings/0001437749-25-015356.md) | [(5.5)](/filings/0001437749-25-025422.md) | [(3.6)](/filings/0001437749-25-033499.md) | [(3.0) d](/filings/0001437749-26-007471.md) | [(3.1)](/filings/0001437749-26-015652.md) | [(2.6)](/filings/0001437749-26-026346.md) | [(0.8)](/filings/0001437749-25-033499.md) | [0.0 d](/filings/0001437749-26-007471.md) | [(0.9)](/filings/0001437749-26-015652.md) | [(1.8)](/filings/0001437749-26-026346.md) |
| Interest expense | $m | [0.6](/filings/0000719135-23-000056.md) | [1.1 d](/filings/0000719135-24-000016.md) | [1.4](/filings/0000719135-24-000026.md) | [1.4](/filings/0000719135-24-000038.md) | [1.4](/filings/0001437749-25-033499.md) | [1.7 d](/filings/0001437749-26-007471.md) | [1.4](/filings/0001437749-26-015652.md) | [1.4](/filings/0001437749-26-026346.md) | [1.4](/filings/0001437749-25-033499.md) | [1.4 d](/filings/0001437749-26-007471.md) | [1.4](/filings/0001437749-26-015652.md) | [1.4](/filings/0001437749-26-026346.md) |
| Income tax | $m | [(0.3)](/filings/0001437749-24-034193.md) | [0.1 d](/filings/0001437749-25-007521.md) | [0.1](/filings/0001437749-25-015356.md) | [0.1](/filings/0001437749-25-025422.md) | [0.1](/filings/0001437749-25-033499.md) | [0.1 d](/filings/0001437749-26-007471.md) | [0.0](/filings/0001437749-26-015652.md) | [0.0](/filings/0001437749-26-026346.md) | [0.1](/filings/0001437749-25-033499.md) | [0.1 d](/filings/0001437749-26-007471.md) | [0.1](/filings/0001437749-26-015652.md) | [0.1](/filings/0001437749-26-026346.md) |
| Net income | $m | [(4.6)](/filings/0001437749-24-034193.md) | [(9.6) d](/filings/0001437749-25-007521.md) | [(7.6)](/filings/0001437749-25-015356.md) | [(6.6)](/filings/0001437749-25-025422.md) | [(4.7)](/filings/0001437749-25-033499.md) | [(4.6) d](/filings/0001437749-26-007471.md) | [(4.2)](/filings/0001437749-26-015652.md) | [(3.8)](/filings/0001437749-26-026346.md) | [(2.0)](/filings/0001437749-25-033499.md) | [(1.3) d](/filings/0001437749-26-007471.md) | [(2.1)](/filings/0001437749-26-015652.md) | [(3.2)](/filings/0001437749-26-026346.md) |
| Diluted EPS | $ per share | [(0.13)](/filings/0000719135-23-000056.md) | not reported | [(0.22)](/filings/0000719135-24-000026.md) | [(0.19)](/filings/0000719135-24-000038.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.13)](/filings/0001437749-24-034193.md) | not reported | [(0.22)](/filings/0001437749-25-015356.md) | [(0.19)](/filings/0001437749-25-025422.md) | [(0.14)](/filings/0001437749-25-033499.md) | not reported | [(0.10)](/filings/0001437749-26-015652.md) | [(0.09)](/filings/0001437749-26-026346.md) | [(0.05)](/filings/0001437749-25-033499.md) | not reported | [(0.05)](/filings/0001437749-26-015652.md) | [(0.07)](/filings/0001437749-26-026346.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [22.1](/filings/0000719135-23-000056.md) | [43.7](/filings/0001437749-25-007521.md) | [37.3](/filings/0000719135-24-000026.md) | [32.7](/filings/0000719135-24-000038.md) | [28.0](/filings/0001437749-24-034193.md) | [31.7](/filings/0001437749-26-007471.md) | [31.0](/filings/0001437749-25-015356.md) | [29.3](/filings/0001437749-25-025422.md) | [25.1](/filings/0001437749-25-033499.md) | [31.7](/filings/0001437749-26-026346.md) | [31.1](/filings/0001437749-26-015652.md) | [27.6](/filings/0001437749-26-026346.md) |
| Current assets | $m | [50.2](/filings/0000719135-23-000056.md) | [70.4](/filings/0001437749-25-007521.md) | [61.9](/filings/0000719135-24-000026.md) | [56.7](/filings/0000719135-24-000038.md) | [52.2](/filings/0001437749-24-034193.md) | [56.4](/filings/0001437749-26-007471.md) | [51.9](/filings/0001437749-25-015356.md) | [49.9](/filings/0001437749-25-025422.md) | [48.8](/filings/0001437749-25-033499.md) | [58.5](/filings/0001437749-26-026346.md) | [54.8](/filings/0001437749-26-015652.md) | [53.2](/filings/0001437749-26-026346.md) |
| Total assets | $m | [59.4](/filings/0000719135-23-000056.md) | [79.2](/filings/0001437749-25-007521.md) | [70.7](/filings/0000719135-24-000026.md) | [65.4](/filings/0000719135-24-000038.md) | [60.7](/filings/0001437749-24-034193.md) | [64.8](/filings/0001437749-26-007471.md) | [60.2](/filings/0001437749-25-015356.md) | [58.2](/filings/0001437749-25-025422.md) | [57.4](/filings/0001437749-25-033499.md) | [66.8](/filings/0001437749-26-026346.md) | [63.0](/filings/0001437749-26-015652.md) | [61.1](/filings/0001437749-26-026346.md) |
| Current liabilities | $m | [10.3](/filings/0000719135-23-000056.md) | [12.7](/filings/0001437749-25-007521.md) | [10.6](/filings/0000719135-24-000026.md) | [10.6](/filings/0000719135-24-000038.md) | [9.6](/filings/0001437749-24-034193.md) | [10.7](/filings/0001437749-26-007471.md) | [9.5](/filings/0001437749-25-015356.md) | [10.6](/filings/0001437749-25-025422.md) | [11.0](/filings/0001437749-25-033499.md) | [11.7](/filings/0001437749-26-026346.md) | [9.4](/filings/0001437749-26-015652.md) | [9.4](/filings/0001437749-26-026346.md) |
| Total liabilities | $m | [25.9](/filings/0000719135-23-000056.md) | [52.3](/filings/0001437749-25-007521.md) | [50.3](/filings/0000719135-24-000026.md) | [50.5](/filings/0000719135-24-000038.md) | [49.5](/filings/0001437749-24-034193.md) | [50.5](/filings/0001437749-26-007471.md) | [49.5](/filings/0001437749-25-015356.md) | [50.7](/filings/0001437749-25-025422.md) | [51.3](/filings/0001437749-25-033499.md) | [52.0](/filings/0001437749-26-026346.md) | [49.9](/filings/0001437749-26-015652.md) | [50.0](/filings/0001437749-26-026346.md) |
| Long-term debt | $m | [9.0](/filings/0000719135-23-000056.md) | [33.2](/filings/0001437749-25-007521.md) | [33.4](/filings/0000719135-24-000026.md) | [33.6](/filings/0000719135-24-000038.md) | [33.9](/filings/0001437749-24-034193.md) | [33.9](/filings/0001437749-26-007471.md) | [34.1](/filings/0001437749-25-015356.md) | [34.4](/filings/0001437749-25-025422.md) | [34.6](/filings/0001437749-25-033499.md) | [34.8](/filings/0001437749-26-026346.md) | [35.1](/filings/0001437749-26-015652.md) | [35.3](/filings/0001437749-26-026346.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [33.3](/filings/0000719135-23-000056.md) | [26.7](/filings/0001437749-25-007521.md) | [20.3](/filings/0000719135-24-000026.md) | [14.7](/filings/0000719135-24-000038.md) | [11.0](/filings/0001437749-24-034193.md) | [14.2](/filings/0001437749-26-007471.md) | [10.5](/filings/0001437749-25-015356.md) | [7.3](/filings/0001437749-25-025422.md) | [5.8](/filings/0001437749-25-033499.md) | [14.5](/filings/0001437749-26-026346.md) | [12.8](/filings/0001437749-26-015652.md) | [10.7](/filings/0001437749-26-026346.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [3,696 d](/filings/0001437749-24-034193.md) | [(2,212) d](/filings/0001437749-25-007521.md) | [(6,341)](/filings/0001437749-25-015356.md) | [(4,329) d](/filings/0001437749-25-025422.md) | [(4,440) d](/filings/0001437749-25-033499.md) | [(2,937) d](/filings/0001437749-26-007471.md) | [(702)](/filings/0001437749-26-015652.md) | [(1,233) d](/filings/0001437749-26-026346.md) | [(3,536) d](/filings/0001437749-25-033499.md) | [(2,530) d](/filings/0001437749-26-007471.md) | [(572)](/filings/0001437749-26-015652.md) | [(3,490) d](/filings/0001437749-26-026346.md) |
| Capital expenditure | $k | [174 d](/filings/0001437749-24-034193.md) | [93.0 d](/filings/0001437749-25-007521.md) | [35.0](/filings/0001437749-25-015356.md) | [289 d](/filings/0001437749-25-025422.md) | [153 d](/filings/0001437749-25-033499.md) | [245 d](/filings/0001437749-26-007471.md) | [55.0](/filings/0001437749-26-015652.md) | [265 d](/filings/0001437749-26-026346.md) | [519 d](/filings/0001437749-25-033499.md) | [275 d](/filings/0001437749-26-007471.md) | [60.0](/filings/0001437749-26-015652.md) | [66.0 d](/filings/0001437749-26-026346.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2020 (2020-09-30) | Q1 FY2021 (2021-03-31) | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [34.2](/filings/0000719135-21-000072.md) | [34.3](/filings/0000719135-22-000033.md) | [34.3](/filings/0000719135-22-000063.md) | [34.3](/filings/0000719135-22-000091.md) | [34.4](/filings/0000719135-23-000027.md) | [34.5](/filings/0000719135-23-000047.md) | [34.6](/filings/0000719135-23-000056.md) | [34.6](/filings/0000719135-24-000026.md) | [34.6](/filings/0000719135-24-000038.md) | [34.6](/filings/0000719135-23-000056.md) | [34.6](/filings/0000719135-24-000026.md) | [34.6](/filings/0000719135-24-000038.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 42,124,023 at 2026-08-05, from the cover of the [10-Q filed 2026-08-06](/filings/0001437749-26-026346.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:22 ET. No prices; not investment advice.